Skip to main navigation
MENU
x
Investors + Newsroom
Home
Stock Information
News
Events
SEC Filings
Corporate Governance
Shareholder Services
Culture + Careers
Who We Are
Who We Are
PIONEERS IN GENE THERAPY
MISSION & VALUES
MANAGEMENT TEAM
BOARD OF DIRECTORS
Science & Innovation
Science & Innovation
WHAT IS AVV GENE THERAPY?
NAV(R) TECHNOLOGY PLATFORM
PARTNERS & LICENSEES
MANUFACTURING
PUBLICATIONS
Therapeutic Pipeline
Therapeutic Pipeline
RGX-314 FOR RETINAL DISEASES
RGX-202 FOR DUCHENNE
RGX-121 FOR MPSII (HUNTER SYNDROME)
RGX-111 FOR MPSI
RGX-181 FOR CLN2 DISEASE
RGX-381 FOR CLN2 DISEASE
Patients & Families
Patients & Families
WHY GENE THERAPY?
WET AMD
DUCHENNE
MPS II
MPS I
CLN2
EXPANDED ACCESS
Search
Investors + Newsroom
Investors + Newsroom
Home
Stock Information
News
Events
SEC Filings
Corporate Governance
Shareholder Services
Culture + Careers
News
More news releases are coming soon.
Contact Us
Stay connected on REGENXBIO programs and our commitment to patients.
Contact Us
